Business Context and Reporting Period
This Form 8-K Current Report from Corcept Therapeutics Inc. (CORT) covers the 2026 Annual Meeting of Stockholders held on May 21, 2026. The filing details the outcomes of four stockholder proposals, including the election of directors, ratification of auditors, executive compensation approval, and an amendment to the company's incentive award plan.
Key Financial Metrics
This filing is a corporate governance report and does not contain financial performance data such as revenue, profit, cash flow, margins, debt, or liquidity. The filing text does not provide a clear value for any financial metrics.
Material Changes
The primary material change reported is the approval of the Amendment to the Corcept Therapeutics Incorporated 2024 Incentive Award Plan. This amendment increases the number of shares available under the plan by 8,000,000 shares and clarifies certain plan language. The amended plan became effective immediately upon stockholder approval on May 21, 2026.
Outlook, Risks, and Management Commentary
- Director Elections: Stockholders elected eight directors to serve until the 2027 annual meeting. While all nominees received majority support, David L. Mahoney received a significant number of withheld votes (26,216,179) compared to other nominees.
- Auditor Ratification: Stockholders ratified the appointment of Ernst & Young LLP as the independent registered public accounting firm for the fiscal year ending December 31, 2026, with 92,656,473 votes in favor.
- Executive Compensation: The advisory vote on named executive officer compensation was approved with 72,511,429 votes in favor.
- Plan Amendment Vote: The proposal to amend the 2024 Incentive Award Plan passed with 53,163,364 votes in favor, though it faced notable opposition with 23,867,363 votes against.
- Voting Participation: Of 107,356,686 shares entitled to vote, 93,270,175 shares were voted at the meeting.
Investor Verification Checklist
- Verify the specific terms of the 8,000,000 share increase in the Amended 2024 Incentive Award Plan by reviewing Exhibit 10.1.
- Review the Definitive Proxy Statement on Schedule 14A (filed April 17, 2026) for the full text of the plan amendment and rationale.
- Monitor future filings for the impact of the increased share pool on potential dilution.
- Note the significant withheld votes for director David L. Mahoney and the substantial "against" votes for the plan amendment, which may indicate stockholder sentiment issues.